Purpose

This study investigates whether an experimental medication is effective in slowing the progression of preclinical Alzheimer’s Disease in individuals with mild symptoms with or without a family history of AD.

Category

IRB Number
20200461HU
NCT Number
-
Open to Enrollment
Yes
Sponsor
-



Study Contact

Principal Investigator
Arash Salardini

Regulatory Point of Contact
Floyd Jones
210-450-3158
jonesfa@uthscsa.edu



Eligibility

Eligible Ages
55 - 80
Eligible Genders
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

    Participants must have a study partner who is willing to provide information about the individual’s daily activities. ???????

Exclusion Criteria

    Recent history of stroke, seizures, or major psychiatric illness. Inability to complete MRI scans.